Antitumor Effect of Everolimus in Preclinical Models of High-Grade Gastroenteropancreatic Neuroendocrine Carcinomas

Publisher： Karger

E-ISSN： 1423-0194|97|4|331-340

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.97, Iss.4, 2013-01, pp. : 331-340

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas

By  

Neuroendocrinology, Vol. 103, Iss. 2, 2016-01 ,pp. : 186-194

Karger

Access to resources Recommend Favorite

Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor

By  

Neuroendocrinology, Vol. 103, Iss. 5, 2015-08 ,pp. : 452-459

Karger

Access to resources Recommend Favorite

Synergistic Effects of Erlotinib and Everolimus on Bronchial Carcinoids and Large-Cell Neuroendocrine Carcinomas with Activated EGFR/AKT/mTOR Pathway

By  

Neuroendocrinology, Vol. 96, Iss. 3, 2012-02 ,pp. : 228-237

Karger

Access to resources Recommend Favorite

Tumour Biology of Gastroenteropancreatic Neuroendocrine Tumours

By  

Neuroendocrinology, Vol. 80, Iss. 1, 2004-10 ,pp. : 8-11

Karger

Access to resources Recommend Favorite

Epigenetic Aspects on Therapy Development for Gastroenteropancreatic Neuroendocrine Tumors

By  

Neuroendocrinology, Vol. 97, Iss. 1, 2012-03 ,pp. : 19-25

Karger

Access to resources Recommend Favorite